Liquid Biopsy: Page 2

Cancer detection firm Elypta awarded quality certification

By LabPulse.com staff writers

The scope of the certification includes the design and development of in vitro diagnostic (IVD) test kits and software for Elypta’s liquid biopsy-based platform for the detection and measurement of glycosaminoglycans (GAGomes) across different cancers.

July 7, 2023

Quest Diagnostics completes acquisition of Haystack Oncology, adds MRD liquid biopsy to Dx portfolio

By LabPulse.com staff writers

Quest expects next year to use the MRD technology in blood-based clinical lab testing services for solid tumor cancers.

June 21, 2023

Myriad Genetics, MD Anderson collaborate on metastatic renal cell carcinoma research

By LabPulse.com staff writers

The project will use Myriad’s minimal residual disease testing platform, a tumor-informed high-definition assay that detects circulating tumor DNA.

June 12, 2023

Foundation Medicine enters companion diagnostic collaboration with Merck KGaA

By LabPulse.com staff writers

The agreement builds on a partnership the firms entered in 2020 to accelerate the development of novel targeted therapies.

June 5, 2023

Devyser, Thermo Fisher ink collaboration, distribution agreement

By LabPulse.com staff writers

The agreement gives Thermo Fisher Scientific the exclusive rights to commercialize Devyser's post-transplant portfolio of next-generation sequencing products in North America and Europe.

April 24, 2023

Karius, eGenesis to develop infectious disease diagnostic tests for xenotransplantation

By LabPulse.com staff writers

Through the partnership, Karius will leverage its testing platform to enable the detection and quantification of pathogens with potential to occur in porcine organ donors.

April 11, 2023

GC Genome liquid biopsy technology in study predicts solid tumor radiation therapy response

By LabPulse.com staff writers

The research conducted in collaboration with the Samsung Medical Center, Sungkyunkwan University School of Medicine, used I-score, a tool for calculating genomic instabilities developed by GC Genome.

April 10, 2023

OraSure, nRichDx to offer products for researchers developing urine-based liquid biopsy assays

By LabPulse.com staff writers

The firms noted that their products use first-void urine, which is enriched in biomarkers suitable for molecular analysis by people researching sexually-transmitted infections, human papillomavirus, and early stage cancers.

March 27, 2023

Guardant Health, Ohio State University study colorectal cancer screening adherence

By LabPulse.com staff writers

The Ohio State University-led study will evaluate changes in CRC screening adherence in underserved urban and rural communities. Guardant Health is providing its Shield blood test to eligible individuals through mobile health clinic partners.

March 21, 2023

Natera receives commercial payor coverage for molecular residual disease test

By LabPulse.com staff writers

Among the first commercial coverage policies for the test, Blue Shield of California began providing coverage of Signatera for plan members diagnosed with solid tumors.

March 2, 2023

UnitedHealthcare increases coverage for Guardant360 CDx liquid biopsy test

By LabPulse.com staff writers

The new policy coverage by UnitedHealthcare is in addition to coverage for the liquid biopsy CDx test under UHC Medicare Advantage policies for comprehensive genomic profiling of all solid tumors.

February 8, 2023

Geneseeq nabs CE Marks for minimal residual disease, early cancer detection tests

By LabPulse.com staff writers

The firm has received CE Marks for liquid biopsy multicancer minimal residual disease detection and multicancer early detection kits to detect patients with solid tumors.

January 24, 2023

Previous Page

Page 2 of 5

Next Page